iShares Biotechnology ETF
891 hedge funds and large institutions have $5.32B invested in iShares Biotechnology ETF in 2024 Q1 according to their latest regulatory filings, with 101 funds opening new positions, 245 increasing their positions, 308 reducing their positions, and 66 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
891
Holders Change
+26
Holders Change %
+3.01%
% of All Funds
12.91%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.16%
New
101
Increased
245
Reduced
308
Closed
66
Calls
$222M
Puts
$1.07B
Net Calls
-$848M
Net Calls Change
+$220M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$142M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$92.7M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$57.6M |
| 4 |
Citigroup
New York
|
+$51.5M |
| 5 |
Two Sigma Investments
New York
|
+$42.2M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$335M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$109M |
| 3 |
JPMorgan Chase & Co
New York
|
-$57.5M |
| 4 |
IUHSA
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
|
-$29.2M |
| 5 |
MPM
MBB Public Markets
Chicago,
Illinois
|
-$18.9M |